Pharmacokinetic study of sodium trans[tetrachlorobis(1H-indazole)-ruthenate (III)]/-indazole hydrochloride (1:1.1) (FFC14A) in patients with solid tumors.
Henke
M M
MM
Universitatsklinikum Essen, Essen, Germany. magdalena.henke@uni.essen.de
Richly
H
H
Drescher
A
A
Grubert
M
M
Alex
D
D
Thyssen
D
D
Jaehde
U
U
Scheulen
M E
ME
Hilger
R A
RA
D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood / Q000737:chemistry; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D018736:DNA Adducts / Q000097:blood / Q000737:chemistry; D004305:Dose-Response Relationship, Drug; D006207:Half-Life; D006801:Humans; D007191:Indazoles / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D007262:Infusions, Intravenous; D007962:Leukocytes / Q000737:chemistry; D008657:Metabolic Clearance Rate; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D009942:Organometallic Compounds; D017975:Ruthenium Compounds / Q000008:administration & dosage / Q000737:chemistry / Q000493:pharmacokinetics* / Q000627:therapeutic use; D012709:Serum Albumin / Q000032:analysis / Q000737:chemistry / Q000378:metabolism; D014168:Transferrin / Q000032:analysis / Q000737:chemistry / Q000378:metabolism
D000970:Antineoplastic Agents; D015415:Biomarkers; D018736:DNA Adducts; D007191:Indazoles; D009942:Organometallic Compounds; D017975:Ruthenium Compounds; D012709:Serum Albumin; D014168:Transferrin; C499292:indazolium trans-(tetrachlorobis(1H-indazole)ruthenate (III))